The China Mail - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.672503
AFN 63.999659
ALL 82.446914
AMD 367.889616
ANG 1.790403
AOA 917.497004
ARS 1483.7393
AUD 1.444941
AWG 1.8
AZN 1.70203
BAM 1.715719
BBD 2.014659
BDT 123.237259
BGN 1.69088
BHD 0.377133
BIF 2976.647894
BMD 1
BND 1.294833
BOB 6.927015
BRL 5.183803
BSD 1.000237
BTN 94.653762
BWP 13.556631
BYN 2.932324
BYR 19600
BZD 2.011641
CAD 1.420175
CDF 2275.000056
CHF 0.807755
CLF 0.02341
CLP 921.312404
CNY 6.79395
CNH 6.794015
COP 3438.95
CRC 456.074635
CUC 1
CUP 26.5
CVE 96.734291
CZK 21.24675
DJF 177.720003
DKK 6.54136
DOP 59.627253
DZD 133.17727
EGP 49.1335
ERN 15
ETB 160.107467
EUR 0.87516
FJD 2.24225
FKP 0.75464
GBP 0.754025
GEL 2.639985
GGP 0.75464
GHS 11.325109
GIP 0.75464
GMD 73.502887
GNF 8768.31301
GTQ 7.631137
GYD 209.231633
HKD 7.842855
HNL 26.765154
HRK 6.594599
HTG 130.781681
HUF 311.469501
IDR 17925.1
ILS 2.98005
IMP 0.75464
INR 94.53205
IQD 1310.36086
IRR 1376000.000227
ISK 125.84978
JEP 0.75464
JMD 157.597396
JOD 0.708981
JPY 162.587988
KES 129.47945
KGS 87.449815
KHR 4025.844712
KMF 432.000416
KPW 900.00035
KRW 1547.769879
KWD 0.30975
KYD 0.833593
KZT 479.31644
LAK 22434.12886
LBP 89573.772793
LKR 336.095235
LRD 181.582861
LSL 16.36882
LTL 2.95274
LVL 0.60489
LYD 6.42603
MAD 9.401556
MDL 17.67459
MGA 4243.298842
MKD 53.947973
MMK 2099.487458
MNT 3582.059186
MOP 8.08008
MRU 39.968069
MUR 47.189991
MVR 15.459931
MWK 1734.473214
MXN 17.480715
MYR 4.083897
MZN 63.849698
NAD 16.369466
NGN 1380.47968
NIO 36.809762
NOK 9.900185
NPR 151.417455
NZD 1.760705
OMR 0.384501
PAB 1.000268
PEN 3.418588
PGK 4.393387
PHP 61.518502
PKR 278.14144
PLN 3.76195
PYG 6083.016418
QAR 3.656302
RON 4.5852
RSD 102.686992
RUB 78.695525
RWF 1466.200538
SAR 3.758263
SBD 8.065041
SCR 13.559006
SDG 600.552774
SEK 9.69305
SGD 1.293875
SHP 0.746601
SLE 24.796299
SLL 20969.503664
SOS 571.631598
SRD 37.504498
STD 20697.981008
STN 21.492548
SVC 8.752522
SYP 110.532098
SZL 16.366651
THB 33.231498
TJS 9.242505
TMT 3.51
TND 2.964393
TOP 2.40776
TRY 46.648698
TTD 6.789103
TWD 31.807035
TZS 2624.997998
UAH 44.826936
UGX 3666.127143
UYU 40.153526
UZS 12007.438858
VES 622.24352
VND 26315
VUV 119.95305
WST 2.78094
XAF 575.458928
XAG 0.017427
XAU 0.000251
XCD 2.70255
XCG 1.802639
XDR 0.716236
XOF 575.45388
XPF 104.621836
YER 238.601246
ZAR 16.37881
ZMK 9001.203214
ZMW 18.029889
ZWL 321.999592
  • CMSC

    -0.1228

    21.57

    -0.57%

  • JRI

    0.0900

    12.95

    +0.69%

  • BTI

    -0.9900

    61.75

    -1.6%

  • NGG

    -0.7980

    82.962

    -0.96%

  • BCE

    -0.6700

    21.59

    -3.1%

  • AZN

    -2.1200

    188.83

    -1.12%

  • RIO

    0.5000

    94.79

    +0.53%

  • CMSD

    -0.0500

    21.85

    -0.23%

  • RBGPF

    0.6100

    65.61

    +0.93%

  • GSK

    -0.3750

    52.435

    -0.72%

  • RYCEF

    0.2900

    18.68

    +1.55%

  • VOD

    -0.4800

    13.21

    -3.63%

  • RELX

    0.3250

    31.615

    +1.03%

  • BCC

    -1.5600

    77.7

    -2.01%

  • BP

    -0.4050

    36.945

    -1.1%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

N.Wan--ThChM